Skip to main content
Back
Watch Compare

CERO THERAPEUTICS HOLDINGS, INC.

Data quality: 83%
Also listed as CEROW OTC
CERO
OTC Manufacturing Chemicals
$0.04
▲ $0.00 (9.09%)
Mkt Cap: 770,247.0
Price
$0.04
Mkt Cap
770,247.0
Day Range
$0.03 — $0.04
52-Week Range
$0.03 — $28.40
Volume
346,569
Open $0.03
50D / 200D Avg
$0.04
8.86% below
50D / 200D Avg
$3.14
98.85% below

Quick Summary

Key Takeaways

Negative free cash flow of -186,609.0

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio0.30
Interest Coverage-330.32

Valuation

PE (TTM)
-0.05
Above sector avg (-1.48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -0.1 -1.5
P/B — 1.6
ROE % — -53.4
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -14.71 M
ROE N/A ROA -290.85%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -186,609.0
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.30
Interest Coverage -330.32 Asset Turnover N/A
Working Capital -5.90 M Tangible Book Value -4.54 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.05 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -24.23%
Market Cap 770,247.0 Enterprise Value -1.13 M
Per Share
EPS (Diluted TTM) -90.81 Revenue / Share N/A
FCF / Share -0.01 OCF / Share -0.01
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 1.27%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2021 FY2022
Revenue — — — —
Net Income -7.73 M -2.54 M -315,547.0 -667,736.0
EPS (Diluted) -18.15 — — —
Gross Profit — — — —
Operating Income -15.30 M -2.93 M — —
EBITDA — — — —
R&D Expenses 6.32 M — — —
SG&A Expenses — — — —
D&A — — — —
Interest Expense -21,846.0 — — —
Income Tax — 94,819.0 -16,868.0 599,159.0

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2021 FY2022
Total Assets 6.21 M 8.56 M 180.08 M 42.37 M
Total Liabilities 8.10 M 14.32 M 9.25 M 39.90 M
Shareholders' Equity -1.89 M -14.20 M -7.67 M -10.76 M
Total Debt — — — —
Cash & Equivalents — 96,873.0 1.10 M 475,870.0
Current Assets 3.71 M — 1.36 M 42.37 M
Current Liabilities 7.40 M 5.17 M 98,072.0 30.75 M